These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23616698)

  • 1. New approaches in the treatment of short term and middle of the night insomnia: emerging evidence for a role for sublingual zolpidem tablets.
    Ownby RL
    Nat Sci Sleep; 2010; 2():63-9. PubMed ID: 23616698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zolpidem: Efficacy and Side Effects for Insomnia.
    Edinoff AN; Wu N; Ghaffar YT; Prejean R; Gremillion R; Cogburn M; Chami AA; Kaye AM; Kaye AD
    Health Psychol Res; 2021; 9(1):24927. PubMed ID: 34746488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.
    Roth T; Krystal A; Steinberg FJ; Singh NN; Moline M
    Sleep; 2013 Feb; 36(2):189-96. PubMed ID: 23372266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening.
    Zammit GK; Corser B; Doghramji K; Fry JM; James S; Krystal A; Mangano RM
    J Clin Sleep Med; 2006 Oct; 2(4):417-23. PubMed ID: 17557470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insomnia in Elderly Patients: Recommendations for Pharmacological Management.
    Abad VC; Guilleminault C
    Drugs Aging; 2018 Sep; 35(9):791-817. PubMed ID: 30058034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zolpidem's use for insomnia.
    Monti JM; Spence DW; Buttoo K; Pandi-Perumal SR
    Asian J Psychiatr; 2017 Feb; 25():79-90. PubMed ID: 28262178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Middle-of-the-night administration of sleep medication: a critical review of the effects on next morning driving ability.
    Verster JC; van de Loo AJ; Moline ML; Roth T
    Curr Drug Saf; 2014; 9(3):205-11. PubMed ID: 24909576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Safety and Efficacy of Sleep Medicines in Older Adults.
    Schroeck JL; Ford J; Conway EL; Kurtzhalts KE; Gee ME; Vollmer KA; Mergenhagen KA
    Clin Ther; 2016 Nov; 38(11):2340-2372. PubMed ID: 27751669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States.
    Jhaveri M; Seal B; Pollack M; Wertz D
    Curr Med Res Opin; 2007 Jun; 23(6):1431-43. PubMed ID: 17559740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of middle-of-the-night awakenings on health status, activity impairment, and costs.
    Moline M; DiBonaventura Md; Shah D; Ben-Joseph R
    Nat Sci Sleep; 2014; 6():101-11. PubMed ID: 25093001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial.
    Castro LS; Otuyama LJ; Fumo-Dos-Santos C; Tufik S; Poyares D
    Braz J Psychiatry; 2020 Apr; 42(2):175-184. PubMed ID: 31859791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Main neuroendocrine features and therapy in primary sleep troubles.
    Amihăesei IC; Mungiu OC
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):862-6. PubMed ID: 23272543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zaleplon: a review of its use in the treatment of insomnia.
    Dooley M; Plosker GL
    Drugs; 2000 Aug; 60(2):413-45. PubMed ID: 10983740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Middle-of-the-night hypnotic use in a large national health plan.
    Roth T; Berglund P; Shahly V; Shillington AC; Stephenson JJ; Kessler RC
    J Clin Sleep Med; 2013 Jul; 9(7):661-8. PubMed ID: 23853559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon.
    Terzano MG; Rossi M; Palomba V; Smerieri A; Parrino L
    Drug Saf; 2003; 26(4):261-82. PubMed ID: 12608888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group.
    Elie R; Rüther E; Farr I; Emilien G; Salinas E
    J Clin Psychiatry; 1999 Aug; 60(8):536-44. PubMed ID: 10485636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects.
    Ancoli-Israel S; Walsh JK; Mangano RM; Fujimori M
    Prim Care Companion J Clin Psychiatry; 1999 Aug; 1(4):114-120. PubMed ID: 15014684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need for flexibility in dosing of hypnotic agents.
    Doghramji K
    Sleep; 2000 Feb; 23 Suppl 1():S16-20; discussion S21-2. PubMed ID: 10755804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Importance of Residual Effects When Choosing a Hypnotic: The Unique Profile of Zaleplon.
    Zammit GK; Kramer JA
    Prim Care Companion J Clin Psychiatry; 2001 Apr; 3(2):53-60. PubMed ID: 15014616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent.
    Brielmaier BD
    Proc (Bayl Univ Med Cent); 2006 Jan; 19(1):54-9. PubMed ID: 16424933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.